If you are:
FDB Only When Necessary: AVAILABLE DATA SUGGEST NO KNOWN RISK; OTC PRODUCT, NO FDA PREGNANCY WARNINGS
FDB Only When Necessary: NO FDA CATEGORY; INCR RISK OF RETROLENTAL FIBROPLASIA SEEN IN PREMATURE INFANTS
No Known Risk: LOW LEVELS EXCRETED WITH LOW RISK FOR ADVERSE EFFECTS IN INFANT
Precaution: USE IS NOT RECOMMENDED; MAY CAUSE UNUSUAL EXCITEMENT OR IRRITABILITY
An adult over 60:
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
management or monitoring precaution: Hepatic-Elderly are more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose of 3000mg is advised.
Giving acetaminophen-pamabrom-pyrilam tablet to a child under 12:
management or monitoring precaution: Use weight based dosing in children less than 12 years.
Contraindication: Do not use in pediatrics <6 years of age unless clinician consultation.
management or monitoring precaution: Consult clinician prior to use. Limited safety data,
Contraindication: Possible CNS excitation and seizure risk in newborns.